Telo Genomics Corp (TSE:TELO) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telo Genomics Corp has announced the inclusion of its TeloViewSMM test for detecting high-risk smoldering multiple myeloma (SMM) patients in the CAP’s approved list of laboratory tests. This approval allows the test, which has demonstrated high sensitivity and specificity, to be used in U.S. hospitals and clinics. The TeloViewSMM test aids in the timely treatment of high-risk patients and monitoring of low-risk patients, potentially improving myeloma disease management.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.